INTENSITY THERAPEUTICS, INC. business relationships
Companies named in INTENSITY THERAPEUTICS, INC.’s 10-K filed 2026-03-27, and public companies whose annual reports name INTENSITY THERAPEUTICS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 2 / 100 Top 5% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in INTENSITY THERAPEUTICS, INC.’s annual report 2
“Clinical Trial Collaboration and Supply Agreement, dated April 13, 2020, between the Registrant and Bristol-Myers Squibb Company (incorporated by reference to Exhibit 10.8 of our Form S-1 filed on June 29, 2023).” SEC filing
“In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon c...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.